TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10078798

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Simple Advice (SA)
Number of subjects: 229
Study: 7805081

Group type: EXPERIMENTAL
Intervention: Less intense anticoagulant regimens with or without concomitant antiplatelet therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants for tissue valves
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants for mechanical valves
Number of subjects: 0
Study: 2783701

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 18
Study: 1012648

Group type: EXPERIMENTAL
Intervention: VP-16
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: VCR plus ADR
Number of subjects: 39

Group type: COMPARATOR
Intervention: Crossover from VP-16 to VCR plus ADR
Number of subjects: 39

Group type: COMPARATOR
Intervention: Crossover from VCR plus ADR to VP-16
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both treatment programs
Number of subjects: 39
Study: 14725502

Group type: EXPERIMENTAL
Intervention: Experimental groups (group I, II, III)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (group IV)
Number of subjects: 50
Study: 29767376

Group type: EXPERIMENTAL
Intervention: Integrated Employment Success Tool (IEST™)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Support as usual
Number of subjects: 84
Study: 27687346

Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation-volume guaranteed (PCV-VG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Volume controlled ventilation (VCV)
Number of subjects: 40
Study: 24916555

Group type: EXPERIMENTAL
Intervention: Cranberry leaf extract beverage
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low-calorie cranberry juice cocktail (LCJC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cranberry beverages (both types)
Number of subjects: 12
Study: 22264219

Group type: EXPERIMENTAL
Intervention: Environmental enrichment intervention during rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Environmental enrichment intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual rehabilitation environment (control)
Number of subjects: 0
Study: 22477921

Group type: EXPERIMENTAL
Intervention: Training of primary care and community health workers about mental health
Number of subjects: 1877
Study: 18415809

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation for medical group
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation for surgical group
Number of subjects: 1218

Group type: COMPARATOR
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 1218

Group type: COMPARATOR
Intervention: Factors affecting adherence to rehabilitation
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Mortality and maximal exercise capacity
Number of subjects: 1218
Study: 15621326

Group type: EXPERIMENTAL
Intervention: Tandem stance for 30 seconds in healthy elderly adults
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Tandem stance for 30 seconds in healthy young adults
Number of subjects: 53

Group type: COMPARATOR
Intervention: Both groups during tandem stance
Number of subjects: 53
Study: 12177586

Group type: EXPERIMENTAL
Intervention: Agomelatine 25 mg once a day
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 711

Group type: COMPARATOR
Intervention: Agomelatine (1 mg, 5 mg, 25 mg)
Number of subjects: 711
Study: 10457138

Group type: EXPERIMENTAL
Intervention: Manual tangential pressure over the perilesional skin before biopsy (Group A)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Biopsy without tangential pressure technique (Group B)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Tangential pressure technique before biopsy (Group C - control)
Number of subjects: 74
Study: 7610473

Group type: EXPERIMENTAL
Intervention: Isocaloric enteral feeding with 52 gr protein for 2000 kcal
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Isocaloric enteral feeding with 35 gr protein for 2000 kcal
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Isocaloric enteral feeding with 80 gr protein for 2000 kcal
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Daily administration of 50 gr protein for 2000 kcal
Number of subjects: 67
Study: 2231217

Group type: EXPERIMENTAL
Intervention: Cisapride (7.5 to 10 mg) three times daily for 6 months
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo three times daily for 6 months
Number of subjects: 17
Study: 302373

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) 2 Gm administered 1/2 hour prior to cardiopulmonary bypass (CPB)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no MP treatment)
Number of subjects: 150
Study: 31090968

Group type: EXPERIMENTAL
Intervention: Potential financial incentives for meeting performance goals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly alerts to providers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions (financial incentives and weekly alerts)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no interventions)
Number of subjects: 0
Study: 31402292

Group type: EXPERIMENTAL
Intervention: NIPPV
Number of subjects: 56

Group type: COMPARATOR
Intervention: Nasal cannula (control)
Number of subjects: 56
Study: 27207449

Group type: EXPERIMENTAL
Intervention: DMF 240 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DMF 240 mg TID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glatiramer acetate (GA)
Number of subjects: 0
Study: 25790673

Group type: EXPERIMENTAL
Intervention: Nourishing Xin and Shen method (NXSM)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Donepezil hydrochloride
Number of subjects: 54

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 54
Study: 23521816

Group type: EXPERIMENTAL
Intervention: Clinical parameters
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Routine laboratory markers
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Specific biomarkers
Number of subjects: 1015
Study: 21644304

Group type: EXPERIMENTAL
Intervention: Electroacupuncture with needle-retaining time of 30 min (120 min total)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Electroacupuncture with needle-retaining time of 10 min (40 min total)
Number of subjects: 52
Study: 18725185

Group type: EXPERIMENTAL
Intervention: Dim Light Melatonin Onset (DLMO) Test
Number of subjects: 56
Study: 16673682

Group type: EXPERIMENTAL
Intervention: Brief physiotherapy intervention
Number of subjects: 268

Group type: COMPARATOR
Intervention: Usual physiotherapy
Number of subjects: 268
Study: 15063428

Group type: EXPERIMENTAL
Intervention: Atorvastatin (n = 28)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Bezafibrate (n = 30)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cultured ECs stimulated with TNF-alpha
Number of subjects: 87
Study: 11534937

Group type: EXPERIMENTAL
Intervention: Pre-thickened fluids
Number of subjects: 24

Group type: COMPARATOR
Intervention: Powder-thickened fluids
Number of subjects: 24
Study: 9130688

Group type: EXPERIMENTAL
Intervention: 5-Aza-2'-deoxycytidine combined with amsacrine (n=30)
Number of subjects: 63
Study: 8179230

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 200 micrograms, twice daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Fluticasone propionate, 200 micrograms, once daily
Number of subjects: 90
Study: 3328342

Group type: EXPERIMENTAL
Intervention: Artemether
Number of subjects: 62

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 62
Study: 29601511

Group type: EXPERIMENTAL
Intervention: Height-adaptive step length measurement method
Number of subjects: 30
Study: 27797787

Group type: EXPERIMENTAL
Intervention: Low intensity pulsed ultrasound (LIPUS)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 501
Study: 25095718

Group type: COMPARATOR
Intervention: Transarterial chemoembolization (TACE)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Selective internal radiotherapy (SIRT)
Number of subjects: 24
Study: 23570437

Group type: EXPERIMENTAL
Intervention: Degarelix
Number of subjects: 0

Group type: COMPARATOR
Intervention: Leuprolide
Number of subjects: 0
Study: 20503397

Group type: EXPERIMENTAL
Intervention: Supplement containing isoflavones and curcumin
Number of subjects: 85
Study: 17532166

Group type: EXPERIMENTAL
Intervention: PSE using PVA particles
Number of subjects: 60

Group type: COMPARATOR
Intervention: PSE using gelfoam particles
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PSE using PVA particles and gelfoam particles
Number of subjects: 60
Study: 16226371

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3mg/kg per dose PO BID from the second day of admission until discharge
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 12645716

Group type: EXPERIMENTAL
Intervention: PMEA-coated circuits (group P)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Uncoated circuits (group U)
Number of subjects: 22
Study: 10389911

Group type: EXPERIMENTAL
Intervention: HER-2/neu peptide-based vaccine
Number of subjects: 8
Study: 8916623

Group type: EXPERIMENTAL
Intervention: Treatment for anxiety disorders
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (80 participants)
Number of subjects: 151
Study: 1876247

Group type: EXPERIMENTAL
Intervention: Intrathecally administered morphine 0.125 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Intrathecally administered morphine 0.25 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Intrathecally administered morphine 0.5 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Systemic narcotic administration
Number of subjects: 56
Study: 6819276

Group type: EXPERIMENTAL
Intervention: 14 MeV d + T fast neutrons; Dosage: 18 to more than 22 Gy; Treatment method: two parallel opposed ports
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: High dose neutrons; Treatment method: randomized in a three arm trial
Number of subjects: 400

Group type: COMPARATOR
Intervention: Neutron irradiation
Number of subjects: 400
Study: 31594635

Group type: EXPERIMENTAL
Intervention: Relugolix (40 mg once daily for 12 weeks)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 28993005

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 217
Study: 26754625

Group type: EXPERIMENTAL
Intervention: LCZ696
Number of subjects: 0

Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 0
Study: 24122836

Group type: EXPERIMENTAL
Intervention: Amoxicillin 750 mg bid
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 mg tid
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 mg qid
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Amoxicillin 750 mg bid with metronidazole 250 mg bid
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 mg tid with metronidazole 250 mg bid
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 mg qid with metronidazole 250 mg bid
Number of subjects: 312
Study: 21767044

Group type: EXPERIMENTAL
Intervention: Concrete thinking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abstract thinking
Number of subjects: 0
Study: 19842006

Group type: EXPERIMENTAL
Intervention: Insurance availability
Number of subjects: 3545

Group type: EXPERIMENTAL
Intervention: Insured with eight or more doctor visits
Number of subjects: 3545

Group type: COMPARATOR
Intervention: Uninsured
Number of subjects: 3545
Study: 17536453

Group type: EXPERIMENTAL
Intervention: HIF-1 alpha expression in papillary thyroid carcinoma (group I)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: VEGF expression in papillary thyroid carcinoma (group I)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: VEGF-C expression in papillary thyroid carcinoma (group I)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: HIF-1 alpha, VEGF, and VEGF-C expression in carcinoma patients with lymph node metastasis
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Correlation of VEGF and VEGF-C expression with HIF-1 alpha
Number of subjects: 73
Study: 15334432

Group type: EXPERIMENTAL
Intervention: Long-term, high-intensity exercises
Number of subjects: 1191

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1191
Study: 11843929

Group type: EXPERIMENTAL
Intervention: Topical oxymetazoline (decongestion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ipsilateral isometric exercise (congestion)
Number of subjects: 20
Study: 9542322

Group type: EXPERIMENTAL
Intervention: IFN alpha‐2b 3 megaunits (MU) subcutaneously three times a week (group A)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: IFN alpha‐2b 3 MU/day until disease progression (group B)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: IFN dose > or = 30 MU/month
Number of subjects: 52

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 52
Study: 8117231

Group type: EXPERIMENTAL
Intervention: Aspartame (NutraSweet)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethanol (0.1% BAL)
Number of subjects: 0
Study: 3291557

Group type: EXPERIMENTAL
Intervention: Propafenone, 150 mg four times daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Disopyramide, 100 mg four times daily
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 38

Group type: COMPARATOR
Intervention: Disopyramide
Number of subjects: 38
Study: 1425004

Group type: EXPERIMENTAL
Intervention: Levo-praziquantel
Number of subjects: 70

Group type: COMPARATOR
Intervention: Praziquantel
Number of subjects: 70
Study: 330483

Group type: EXPERIMENTAL
Intervention: amoxycillin 250 mg and pivmecillinam 200 mg
Number of subjects: 132

Group type: COMPARATOR
Intervention: amoxycillin 500 mg
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: amoxycillin 500 mg and pivmecillinam 400 mg
Number of subjects: 132
Study: 31547438

Group type: EXPERIMENTAL
Intervention: Sodium restriction (dietary counseling)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg daily)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combined therapy (sodium restriction + hydrochlorothiazide)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (regular sodium intake)
Number of subjects: 45
Study: 28145162

Group type: EXPERIMENTAL
Intervention: Corticosteroids plus standard treatment (TMP/SMX)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard treatment plus placebo
Number of subjects: 78
Study: 26031955

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 51
Study: 24266960

Group type: COMPARATOR
Intervention: Intensive blood pressure lowering (target systolic < 125 mmHg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Guideline blood pressure lowering (target systolic < 140 mmHg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intensive lipid lowering (target LDL-c < 1.4 mmol/l)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Guideline lipid lowering (target LDL-c < 3 mmol/l)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering therapy for hemorrhagic stroke
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering therapy for ischemic stroke
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Feasibility of recruitment and retention of participants
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tolerability and safety of the interventions
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Maintaining differences in systolic blood pressure (> 10 mmHg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Maintaining differences in LDL-c (> 1 mmol/l)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Performing clinic and telephone follow-up of cognition measures
Number of subjects: 100
Study: 21249389

Group type: EXPERIMENTAL
Intervention: Exercise at 60% peak oxygen uptake
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exercise at 80% peak oxygen uptake
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control condition (fixed workload at 20 W)
Number of subjects: 12
Study: 20836307

Group type: EXPERIMENTAL
Intervention: Treadmill walking exercise training (TWET)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overground walking exercise training (OWET)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional physiotherapy rehabilitation
Number of subjects: 40
Study: 17194902

Group type: EXPERIMENTAL
Intervention: Allogeneic stem-cell transplantation (SCT)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Autologous stem-cell transplantation (SCT)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 106
Study: 15197210

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) supplement 1.09 g administered bid
Number of subjects: 421

Group type: COMPARATOR
Intervention: Megestrol acetate (MA) liquid suspension 600 mg/d
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Combination of EPA and MA
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: EPA
Number of subjects: 421

Group type: COMPARATOR
Intervention: MA
Number of subjects: 421
Study: 11520724

Group type: EXPERIMENTAL
Intervention: Optimal CPAP
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Optimal CPAP after placebo
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo CPAP
Number of subjects: 48
Study: 9781789

Group type: EXPERIMENTAL
Intervention: Erect exercise
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Supine exercise
Number of subjects: 19
Study: 8143399

Group type: EXPERIMENTAL
Intervention: 2.5 mg felodipine ER
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: 5 mg felodipine ER
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: 10 mg felodipine ER
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study: 3278186

Group type: EXPERIMENTAL
Intervention: Interferon alpha-n1 (Wellferon) at a dose of 5 MU/m2 daily for 28 days and three times weekly for 5 months
Number of subjects: 66

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 66
Study: 31165350

Group type: EXPERIMENTAL
Intervention: Phenylephrine (PE)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ephedrine (E)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison of PE to E
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison of E to PE
Number of subjects: 28
Study: 29569116

Group type: EXPERIMENTAL
Intervention: High-velocity (HV) resistance training
Number of subjects: 53

Group type: COMPARATOR
Intervention: Active control (AC)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Low-velocity (LV) resistance training
Number of subjects: 53
Study: 28526381

Group type: EXPERIMENTAL
Intervention: L-GSH supplementation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 25825328

Group type: EXPERIMENTAL
Intervention: Passive anterior loading of the knee (5 sessions per week for 3 months)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 22
Study: 23731242

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (non-activated laser/only photosensitizer)
Number of subjects: 37
Study: 21596468

Group type: EXPERIMENTAL
Intervention: Experimental Group 1 (EG1) - 4 standard PE sessions/week
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Experimental Group 2 (EG2) - 4 high-intensity PE sessions/week
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control Group - standard PE (2 sessions/week)
Number of subjects: 67
Study: 19885781

Group type: EXPERIMENTAL
Intervention: Strength training (S)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Endurance training (E)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined training (S+E)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 30
Study: 16456024

Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 18
Study: 15388303

Group type: EXPERIMENTAL
Intervention: Working memory and literacy measures
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Executive function measures
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Phonological loop and visual spatial sketchpad measures
Number of subjects: 151
Study: 10761969

Group type: COMPARATOR
Intervention: Rarely/Never alcohol consumption
Number of subjects: 20951

Group type: EXPERIMENTAL
Intervention: 1 to 3 drinks per month
Number of subjects: 20951

Group type: EXPERIMENTAL
Intervention: 1 drink per week
Number of subjects: 20951

Group type: EXPERIMENTAL
Intervention: 2 to 4 drinks per week
Number of subjects: 20951

Group type: EXPERIMENTAL
Intervention: 5 to 6 drinks per week
Number of subjects: 20951

Group type: EXPERIMENTAL
Intervention: 1 or more drinks per day
Number of subjects: 20951
Study: 9017724

Group type: EXPERIMENTAL
Intervention: Frenetic music (2:8 time)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Mellow music (4:4 time)
Number of subjects: 34

Group type: COMPARATOR
Intervention: White noise
Number of subjects: 34
Study: 1503442

Group type: EXPERIMENTAL
Intervention: Imipenem (500 mg four times daily)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Combination therapy (gentamicin 80 mg every 8 h plus either cefuroxime 1,500 mg every 8 h or cephalothin 1,000 mg every 4 h)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 87

Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 87
Study: 6722478

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy plus segmental gastrectomy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Proximal gastric vagotomy
Number of subjects: 28
Study: 29098353

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 88
Study: 27788299

Group type: EXPERIMENTAL
Intervention: Personalized risk calculator
Number of subjects: 375

Group type: COMPARATOR
Intervention: General OA risk information (Control)
Number of subjects: 375